{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T14:27:11Z","timestamp":1793456831780,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T00:00:00Z","timestamp":1565568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.jns.2019.116424","type":"journal-article","created":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T22:00:43Z","timestamp":1565301643000},"page":"116424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":96,"special_numbering":"C","title":["Development of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNIS\u202f+\u202f7"],"prefix":"10.1016","volume":"405","author":[{"given":"P. James B.","family":"Dyck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gonz\u00e1lez-Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Obici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Polydefkis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.F.","family":"Wiesman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Antonino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.J.","family":"Litchy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Dyck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jns.2019.116424_bb0005","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11897-013-0182-4","article-title":"Novel drugs targeting transthyretin amyloidosis","volume":"11","author":"Hanna","year":"2014","journal-title":"Curr. Heart. Fail. Rep."},{"issue":"2","key":"10.1016\/j.jns.2019.116424_bb0010","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s12265-015-9613-9","article-title":"Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis","volume":"8","author":"Damy","year":"2015","journal-title":"J. Cardiovasc. Transl. Res."},{"issue":"8","key":"10.1016\/j.jns.2019.116424_bb0015","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3109\/07853890.2015.1068949","article-title":"Evolving landscape in the management of transthyretin amyloidosis","volume":"47","author":"Hawkins","year":"2015","journal-title":"Ann. Med."},{"issue":"10","key":"10.1016\/j.jns.2019.116424_bb0020","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.acvd.2013.06.051","article-title":"Cardiac amyloidosis: updates in diagnosis and management","volume":"106","author":"Mohty","year":"2013","journal-title":"Arch. Cardiovasc. Dis."},{"issue":"8","key":"10.1016\/j.jns.2019.116424_bb0025","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1212\/WNL.0000000000001870","article-title":"Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study","volume":"85","author":"Adams","year":"2015","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jns.2019.116424_bb0030","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/13506129.2015.1019610","article-title":"Hereditary ATTR amyloidosis: a single-institution experience with 266 patients","volume":"22","author":"Swiecicki","year":"2015","journal-title":"Amyloid"},{"issue":"1","key":"10.1016\/j.jns.2019.116424_bb0035","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jns.12153","article-title":"\"Red-flag\" symptom clusters in transthyretin familial amyloid polyneuropathy","volume":"21","author":"Concei\u00e7\u00e3o","year":"2016","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"6","key":"10.1016\/j.jns.2019.116424_bb0040","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/msj.21352","article-title":"Amyloid neuropathies","volume":"79","author":"Shin","year":"2012","journal-title":"Mt Sinai J. Med."},{"issue":"2","key":"10.1016\/j.jns.2019.116424_bb0045","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10741-014-9462-7","article-title":"Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs","volume":"20","author":"Castano","year":"2015","journal-title":"Heart Fail. Rev."},{"issue":"Suppl. 1","key":"10.1016\/j.jns.2019.116424_bb0050","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1097\/WCO.0000000000000289","article-title":"First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy","volume":"29","author":"Adams","year":"2016","journal-title":"Curr. Opin. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2019.116424_bb0055","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3109\/13506129.2014.964858","article-title":"Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis","volume":"21","author":"Sipe","year":"2014","journal-title":"Amyloid"},{"issue":"3","key":"10.1016\/j.jns.2019.116424_bb0060","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/brain\/75.3.408","article-title":"A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves","volume":"75","author":"Andrade","year":"1952","journal-title":"Brain"},{"key":"10.1016\/j.jns.2019.116424_bb0065","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin-related hereditary amyloidosis for clinicians","volume":"8","author":"Ando","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.jns.2019.116424_bb0070","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1185\/03007995.2012.754348","article-title":"THAOS \u2013 the transthyretin amyloidosis outcomes survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis","volume":"29","author":"Coelho","year":"2013","journal-title":"Curr. Med. Res. Opin."},{"issue":"5","key":"10.1016\/j.jns.2019.116424_bb0075","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/archneur.1969.00480110054005","article-title":"Dissociated sensation in amylidosis. Compound action potential, quantitative histologic and teased-fiber, and electron microscopic studies of sural nerve biopsies","volume":"20","author":"Dyck","year":"1969","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2019.116424_bb0080","series-title":"Amyloid and Amyloidosis","first-page":"88","article-title":"Forty years of experience with type I amyloid neuropathy: review of 483 cases","author":"Coutinho","year":"1980"},{"issue":"2","key":"10.1016\/j.jns.2019.116424_bb0085","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/1756285612470192","article-title":"Recent advances in the treatment of familial amyloid polyneuropathy","volume":"6","author":"Adams","year":"2013","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"11","key":"10.1016\/j.jns.2019.116424_bb0090","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1111\/j.1600-6143.2007.01969.x","article-title":"Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years","volume":"7","author":"Yamamoto","year":"2007","journal-title":"Am. J. Transplant."},{"issue":"8","key":"10.1016\/j.jns.2019.116424_bb0095","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"issue":"24","key":"10.1016\/j.jns.2019.116424_bb0100","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jns.2019.116424_bb0105","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1212\/WNL.49.1.229","article-title":"Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort","volume":"49","author":"Dyck","year":"1997","journal-title":"Neurology"},{"issue":"21","key":"10.1016\/j.jns.2019.116424_bb0110","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1056\/NEJM199111213252105","article-title":"Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance","volume":"325","author":"Dyck","year":"1991","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.jns.2019.116424_bb0115","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/ana.410360607","article-title":"A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"36","author":"Dyck","year":"1994","journal-title":"Ann. Neurol."},{"issue":"9","key":"10.1016\/j.jns.2019.116424_bb0120","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.2337\/dc11-0503","article-title":"Efficacy and safety of antioxidant treatment with \u03b1-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial","volume":"34","author":"Ziegler","year":"2011","journal-title":"Diab. Care"},{"issue":"1\u20132","key":"10.1016\/j.jns.2019.116424_bb0125","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jns.2014.06.041","article-title":"Retrospective study of a TTR FAP cohort to modify NIS\u202f+\u202f7 for therapeutic trials","volume":"344","author":"Suanprasert","year":"2014","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.jns.2019.116424_bb0130","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12883-017-0948-5","article-title":"Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy","volume":"17","author":"Adams","year":"2017","journal-title":"BMC Neurol."},{"issue":"5","key":"10.1016\/j.jns.2019.116424_bb0135","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/mus.25563","article-title":"Assessing mNIS\u202f+\u202f7Ionis and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial","volume":"56","author":"Dyck","year":"2017","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.jns.2019.116424_bb0140","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1085-9489.2005.0010206.x","article-title":"History of standard scoring, notation, and summation of neuromuscular signs. A current survey and recommendation","volume":"10","author":"Dyck","year":"2005","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"6","key":"10.1016\/j.jns.2019.116424_bb0145","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1212\/WNL.41.6.799","article-title":"The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests","volume":"41","author":"Dyck","year":"1991","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jns.2019.116424_bb0150","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/ana.410380323","article-title":"Diabetic polyneuropathy in controlled clinical trials: consensus report of the peripheral nerve society","volume":"38","author":"Peripheral Nerve Soc.","year":"1995","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2019.116424_bb0155","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.21661","article-title":"Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs NPhys trial investigators","volume":"42","author":"Dyck","year":"2010","journal-title":"Muscle Nerve"},{"issue":"12","key":"10.1016\/j.jns.2019.116424_bb0160","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1001\/archneurol.2012.1481","article-title":"\"Unequivocally abnormal\" vs \"usual\" signs and symptoms for proficient diagnosis of diabetic polyneuropathy: Cl vs N phys trial","volume":"69","author":"Dyck","year":"2012","journal-title":"Arch. Neurol."},{"issue":"17","key":"10.1016\/j.jns.2019.116424_bb0165","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1001\/jama.284.17.2215","article-title":"Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. rhNGF Clinical Investigator Group","volume":"284","author":"Apfel","year":"2000","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.jns.2019.116424_bb0170","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.2337\/dc06-1216","article-title":"Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial","volume":"29","author":"Ziegler","year":"2006","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.jns.2019.116424_bb0175","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1056\/NEJM198602203140801","article-title":"Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"314","author":"Dyck","year":"1986","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jns.2019.116424_bb0180","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1007\/s00415-016-8064-9","article-title":"Monitoring effectiveness and safety of tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area","volume":"263","author":"Cortese","year":"2016","journal-title":"J. Neurol."},{"issue":"Suppl. 1","key":"10.1016\/j.jns.2019.116424_bb0185","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000052074","article-title":"NIS-LL: the primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy","volume":"41","author":"Bril","year":"1999","journal-title":"Eur. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2019.116424_bb0190","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jdiacomp.2015.10.018","article-title":"Predictors of improvement and progression of diabetic polyneuropathy following treatment with alpha-lipoic acid for 4 years in the NATHAN 1 trial","volume":"30","author":"Ziegler","year":"2016","journal-title":"J. Diabetes Complicat."},{"issue":"12","key":"10.1016\/j.jns.2019.116424_bb0195","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1111\/ene.12225","article-title":"Effect on disability and safety of tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy","volume":"20","author":"Lozeron","year":"2013","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2019.116424_bb0200","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jns.2016.01.046","article-title":"Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: a phase III, open-label study","volume":"362","author":"Ando","year":"2016","journal-title":"J. Neurol. Sci."},{"issue":"3","key":"10.1016\/j.jns.2019.116424_bb0205","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/mus.23765","article-title":"A trial of proficiency of nerve conduction: greater standardization still needed","volume":"48","author":"Dyck","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2019.116424_bb0210","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1750-1172-9-61","article-title":"THAOS: gastrointestinal manifestations of transthyretin amyloidosis - common complications of a rare disease","volume":"9","author":"Wixner","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"issue":"6","key":"10.1016\/j.jns.2019.116424_bb0215","first-page":"359","article-title":"Reproducibility of different nerve conduction velocity measurements in healthy test subjects and patients suffering from diabetic polyneuropathy","volume":"37","author":"Husstedt","year":"1997","journal-title":"Electromyogr. Clin. Neurophysiol."},{"issue":"1","key":"10.1016\/j.jns.2019.116424_bb0220","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejpain.2005.02.003","article-title":"Quantitative sensory testing: a comprehensive protocol for clinical trials","volume":"10","author":"Rolke","year":"2006","journal-title":"Eur. J. Pain"},{"issue":"Suppl. 2","key":"10.1016\/j.jns.2019.116424_bb0225","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.3949\/ccjm.76.s2.08","article-title":"Heart rate variability with deep breathing as a clinical test of cardiovagal function","volume":"76","author":"Shields","year":"2009","journal-title":"Cleve. Clin. J. Med."},{"issue":"11","key":"10.1016\/j.jns.2019.116424_bb0230","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.2337\/db13-0352","article-title":"Assessing decreased sensation and increased sensory phenomena in diabetic polyneuropathies","volume":"62","author":"Dyck","year":"2013","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.jns.2019.116424_bb0235","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/mus.23982","article-title":"A multicenter trial of the proficiency of smart quantitative sensation tests","volume":"49","author":"Dyck","year":"2014","journal-title":"Muscle Nerve"},{"issue":"1\u20132","key":"10.1016\/j.jns.2019.116424_bb0240","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/0022-510X(95)00277-9","article-title":"A standard test of heat-pain responses using CASE IV","volume":"136","author":"Dyck","year":"1996","journal-title":"J. Neurol. Sci."},{"issue":"5","key":"10.1016\/j.jns.2019.116424_bb0245","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/mus.25563","article-title":"Assessing mNIS\u202f+\u202f7IONIS and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial","volume":"56","author":"Dyck","year":"2017","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.jns.2019.116424_bb0250","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/13506129.2018.1434140","article-title":"Normal scores of deep breathing tests: beware of dysrhythmia in transthyretin amyloidosis","volume":"25","author":"Wiklund","year":"2018","journal-title":"Amyloid"},{"key":"10.1016\/j.jns.2019.116424_bb0255","series-title":"Patisiran, an Investigational RNAi Therapeutic for Patients with Hereditary Transtyretin-Mediated (hATTR) Amyloidosis: Results from the Phase 3 APOLLO Study","author":"Adams","year":"2018"},{"issue":"1","key":"10.1016\/j.jns.2019.116424_bb0260","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jns.2019.116424_bb0265","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.jns.2019.116424_bb0270","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/mus.25257","article-title":"Clinical measures in transthyretin familial amyloid polyneuropathy","volume":"55","author":"Coelho","year":"2017","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.jns.2019.116424_bb0275","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/jns5.12059","article-title":"Norfolk QOL-DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy","volume":"19","author":"Vinik","year":"2014","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"Suppl. 1","key":"10.1016\/j.jns.2019.116424_bb0280","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/WCO.0000000000000288","article-title":"Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP","volume":"29","author":"Parman","year":"2016","journal-title":"Curr. Opin. Neurol."},{"issue":"12","key":"10.1016\/j.jns.2019.116424_bb0285","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1474-4422(11)70246-0","article-title":"Familial amyloid polyneuropathy","volume":"10","author":"Plant\u00e9-Bordeneuve","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2019.116424_bb0290","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jns.2018.08.031","article-title":"Kind and distribution of cutaneous sensation loss in hereditary transthyretin amyloidosis with polyneuropathy","volume":"394","author":"Pinto","year":"2018","journal-title":"J. Neurol. Sci."},{"issue":"6","key":"10.1016\/j.jns.2019.116424_bb0295","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/mus.24243","article-title":"Proficiency of nerve conduction using standard methods and reference values (Cl. NPhys Trial 4)","volume":"50","author":"Litchy","year":"2014","journal-title":"Muscle Nerve"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X19303569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X19303569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:47:39Z","timestamp":1758383259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X19303569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":59,"alternative-id":["S0022510X19303569"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2019.116424","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNIS\u202f+\u202f7","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2019.116424","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"116424"}}